Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab
Semaglutide Nears Market For Obesity
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.
